nei THIS MONTH IN
PSYCHOPHARMACOLOGY
FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD
June 29, 2020   

Attention deficit-hyperactivity disorder (ADHD) is of significant concern. Pharmacological treatments often leave residual symptoms and are associated with side effects. The FDA has recently approved use of a game-based digital device (EndeavorRx®; Figure) for the treatment of ADHD (primarily inattentive or combined-type) in youths aged 8-12 years. This approval by the FDA marks the first of its kind and paves the way for future digital treatments for ADHD as well as other mental health conditions.

Figure. Screenshot of EndeavorRX®.


>> FDA Press Release


For more information:


This Month in Psychopharmacology: ADHD